Episode Details

Stacy Markel, top exec at Nuvation Bio, cashed in $753K by selling shares from 125K exercised stock options — slashing her direct ownership by 79% — though she still holds 32K shares worth $200K and retains future option potential. This wasn’t impulsive: it was a pre-planned December 2025 trade, her first such sale in five years. Nuvation Bio, a clinical-stage cancer drug developer, remains focused on small molecule therapies targeting multiple cancers.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/905b8b3d32926b4d